【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於老年人。

一代抗組織胺 Allergic conjunctivitis, Allergic rhinitis, Anaphylaxis (Adjunct), Blood transfusion reaction, Common cold, Cutaneous hypersensitivity, Dermatographic urticaria, Vasomotor rhinitis

First generation Histamine H₁ Antagonist
Dexchlorpheniramine maleate, an antihistamine with anticholinergic properties, competes with histamine for receptor sites on effector cells in the control of allergic reaction, aside from inducing slight to moderate sedation

Time to peak concentration: 3 h.
Protein binding: 69% to 72%.
Elimination Half Life: 20 h to 24 h

Hypersensitivity to dexchlorpheniramine products, including racemic chlorpheniramine

B (FDA)

Infant risk cannot be ruled out.

Diarrhea, Epigastric discomfort, Nausea, Vomiting, Xerostomia, Somnolence, Nasal mucosa dry

2 mg every 4 to 6 hours